Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by 40Baggson Apr 14, 2019 2:32pm
263 Views
Post# 29624944

RE:RE:RE:RE:LHS & CC Pharma In Results > Email from IR

RE:RE:RE:RE:LHS & CC Pharma In Results > Email from IRThe 47M divesture of LHS note covers the $28M cc pharma purchase. An additional $35M is due based on performance for CC, but APHA can also recieve additional 10M from the LHS note liquidation. Cash and equivalents could be closer to 200M for Q3. This is a shoe-in hold for LT investors as it will reach profitability long before ACB CGC TLRY.... JMHO. If APHA sold over 5000KG and CC Pharma had a big 7 weeks (~55M), it's possible we match CGCs Q2 revenue. I am curious to see the value CC Pharma adds to Q2 $2.1B balance sheet.


Shadd76 wrote: Disagree. The SP hasn’t had nearly enough run up to generate a sell off, and with BOD announcements coming too, way too much buzz surrounding this company to
generate a sell off tomorrow. 


Bullboard Posts